Q4 2024 IOL Chemicals and Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- The company reported a total income of INR 2,163 crore for FY24, showing resilience despite a slight decline from INR 2,243 crore in FY23.
- EBITDA for FY24 stood at INR 262 crore, an improvement from INR 252 crore in FY23, with EBITDA margins improving by 90 basis points to 12.1%.
- Exports grew by 7% to INR 679 crore in FY24 compared to INR 634 crore in FY23, indicating strong international market performance.
- The company has achieved significant capacity utilization increases in key products like Paracetamol and Metformin, running at 95% capacity.
- IOL Chemicals and Pharmaceuticals Ltd (BOM:524164) has received approvals in the European market and other regulatory markets, which are expected to boost exports and revenue.
- Total income for Q4 FY24 was INR 511 crore, down from INR 596 crore in the corresponding quarter of FY23.
- EBITDA for Q4 FY24 declined to INR 58 crore from INR 104 crore in Q4 FY23, with EBITDA margins dropping by 620 basis points to 11.3%.
- Net profit for Q4 FY24 was INR 28 crore, a significant decrease from INR 65 crore in Q4 FY23.
- The specialty chemical segment showed subdued performance in Q4 FY24 due to inventory overhang and poor spreads, with EBIT margins at a mere 0.48%.
- The company faced increased other expenses due to higher selling and distribution costs and elevated insurance costs stemming from the Red Sea crisis.
Ladies and gentlemen, good day, and welcome to the Q4 and FY24 earnings conference call of IOL Chemicals and Pharmaceuticals Limited. From the management, we have Mr. Pardeep Khanna, Chief Financial Officer; Mr. Abhay Raj Singh, Senior VP and Company Secretary; and Mr. Rakesh Mahajan, Advisor, Finance and Strategic. We also have an Investor Relations team from Adfactors. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Mr. Darshan Mankad from Adfactors PR for the opening remarks. Thank you, and over to you.
Thank you, Mike. Good afternoon, everyone. We welcome you to the fourth quarter and financial year '24 earnings call of IOL Chemicals and Pharmaceuticals Limited. Before we begin the earnings call, I would like to mention that some of the statements made during today's call might be forward-looking in nature and hence it may involve risks and uncertainties, including those related to the future financial and operating performance of the company.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
